Renal Cell Carcinoma (Kidney Cancer)KIDCaDNCT07004426
Symptomatic and Incidental RCC Detection
An observational study of Renal Cell Carcinoma (Kidney Cancer) and Benign Renal Neoplasm, run by Charles University, Czech Republic at 1 site in Czechia.
Trial summary
Evaluation of the frequency of symptomatic and incidental detection of renal carcinoma at different stages depending on the imaging modality used Read more about this study
- Who is it for?
- Ages 18 to 90 years
- Conditions the study is for
- Renal Cell Carcinoma (Kidney Cancer), Benign Renal Neoplasm, Renal Carcinoma
- What is being tested?
- Surgical treatment of renal lesions
- Type of treatment
- Surgery or procedure
- How many people
- 1,000 participants
- Where
- 1 siteCzechia
- Study dates
- 1 Jun 2025to 15 Jul 2025
- How long will I take part?
- 1 Day
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 90 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients treated for renal lesions at the Urology Department of University Hospital Královské Vinohrady
Who may be able to join
- patients over 18 years of age undergoing surgical treatment for renal lesions
Who cannot join
- patients undergoing surgery for non-renal and urotelial carcinoma, including unknown
- patients with recurrent renal lesions
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Assessment of Symptomatic and Incidental Detection of Renal Cell Carcinoma Using Standard Imaging Modalities
Evaluation of the frequency of symptomatic and incidental detection of renal carcinoma at different stages depending on the imaging modality used
Read the detailed description
In the Czech Republic, there is no screening program for renal cell carcinoma. Existing evidence suggests that incidental detection of this cancer tends to occur in its early stages, which are more manageable due to effective treatment options, ultimately reducing renal cancer mortality. This highlights the potential value of evaluating current imaging modalities and determining their role in secondary prevention. This cross-sectional study, based on hospital data, aims to contribute to a better understanding of this issue and to assess the effectiveness of imaging techniques in the early detection of renal cell carcinoma. Furthermore, data analysis may reveal the influence of risk factors on the detection of tumors at various stages.
- Being tested
- Surgical treatment of renal lesions
- Keywords
- Renal cell carcinoma, Detection, Imaging modalities, Non-neoplastic renal lesions
- Medical subject headings
- Carcinoma, Renal Cell, Kidney Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Surgical treatment of renal lesionsProcedure or surgery
Surgical treatment of renal lesions
| Study group | Role | What they receive |
|---|---|---|
| A single patient group undergoing intervention for renal lesions | Not described Receives: Procedure: Surgical treatment of renal lesions |
What is being measured
The primary outcome is the main question the study is designed to answer.
Detection-specific renal cell carcinoma (RCC) proportions
Detection-specific renal cell carcinoma (RCC) proportions, defined as the proportion of each detection type relative to all RCC cases. Results will be stratified by stage, histological type, and imaging modality.
Measured: From 2011 to 2020
Secondary outcomes (1)
Proportion of RCC among neoplastic and non-neoplastic renal lesions
Proportion of RCC among neoplastic and non-neoplastic renal lesions, stratified by investigated covariates (e.g., age, sex, smoking status, BMI, or hypertension treatment).
Measured: From 2011 to 2020
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Jun 2025
- Study start1 Jun 2025
- Primary completion1 Jul 2025
- Study completion15 Jul 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Renal Cell Carcinoma (Kidney Cancer)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 1,000 participants (actual)
- Target duration
- 1 Day
Sponsor and investigators
- Lead sponsor
- Charles University, Czech Republic
- Sponsor type
- University, hospital or other
- Collaborators
- Vascular surgery, University hospital Královské Vinohrady, Prague
- Responsible party
- Sponsor
- Investigators
- Jindřich Šonský, MD, Principal investigator, Vascular surgery, University hospital Královské Vinohrady, PragueAlexandra Gregušová, MD, Study chair, Vascular surgery, University hospital Královské Vinohrady, PragueJakub Hanych, MD, Study chair, Vascular surgery, University hospital Královské Vinohrady, PragueRobert Grill, assoc. prof., MD, PhD, Study director, Vascular surgery, University hospital Královské Vinohrady, PragueKateřina Licková, MD, PhD, Study chair, Vascular surgery, University hospital Královské Vinohrady, PragueJana Malinová, MD, PhD, Study chair, Vascular surgery, University hospital Královské Vinohrady, PragueTomáš Blažek, MD, PhD, Study chair, Ostrava University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07004426
- Sponsor's protocol ID
- KIDCaD
- Acronym
- KIDCaD
- Status last verified
- Jul 2025
- First submitted
- 27 May 2025
- Last updated
- 19 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: The data that support the findings of this study will be available from the principal investigators upon reasonable request.
Study at a glance
From the registry record, last updated by the sponsor on 19 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Assessment of Symptomatic and Incidental Detection of Renal Cell Carcinoma Using Standard Imaging Modalities
- ClinicalTrials.gov ID
- NCT07004426
- Acronym / sponsor ID
- KIDCaD / KIDCaD
- Keywords
- Renal cell carcinoma, Detection, Imaging modalities, Non-neoplastic renal lesions
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 1,000 participants (actual)
- Lead sponsor
- Charles University, Czech RepublicUniversity, hospital or other
- Collaborators
- Vascular surgery, University hospital Královské Vinohrady, Prague
- Study start
- 1 Jun 2025 (actual)
- Primary completion
- 1 Jul 2025 (actual)
- Study completion
- 15 Jul 2025 (actual)
- First posted
- 4 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Evaluation of the frequency of symptomatic and incidental detection of renal carcinoma at different stages depending on the imaging modality used
Detailed description
In the Czech Republic, there is no screening program for renal cell carcinoma. Existing evidence suggests that incidental detection of this cancer tends to occur in its early stages, which are more manageable due to effective treatment options, ultimately reducing renal cancer mortality. This highlights the potential value of evaluating current imaging modalities and determining their role in secondary prevention. This cross-sectional study, based on hospital data, aims to contribute to a better understanding of this issue and to assess the effectiveness of imaging techniques in the early detection of renal cell carcinoma. Furthermore, data analysis may reveal the influence of risk factors on the detection of tumors at various stages.
Study design
- Observational model
- Other
- Time perspective
- Cross-sectional
- Target follow-up
- 1 Day
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| A single patient group undergoing intervention for renal lesions | – | Procedure: Surgical treatment of renal lesions |
Who may qualify
- Ages
- 18 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients treated for renal lesions at the Urology Department of University Hospital Královské Vinohrady
Key inclusion criteria (1 listed)
- patients over 18 years of age undergoing surgical treatment for renal lesions
Key exclusion criteria (2 listed)
- patients undergoing surgery for non-renal and urotelial carcinoma, including unknown
- patients with recurrent renal lesions
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Surgical treatment of renal lesionsSurgical treatment of renal lesions | Procedure or surgery | A single patient group undergoing intervention for renal lesions |
Primary outcome
Detection-specific renal cell carcinoma (RCC) proportions
Time frame: From 2011 to 2020
Detection-specific renal cell carcinoma (RCC) proportions, defined as the proportion of each detection type relative to all RCC cases. Results will be stratified by stage, histological type, and imaging modality.
1 secondary outcome
Proportion of RCC among neoplastic and non-neoplastic renal lesions
Time frame: From 2011 to 2020
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Mar 2026.
- Individual participant dataSharing planned: Yes. The data that support the findings of this study will be available from the principal investigators upon reasonable request.
Related trials for Renal Cell Carcinoma (Kidney Cancer)
RecruitingPhase 2
Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder
Adjustment Disorder, Adjustment Disorder With Anxious Mood
Not yet recruitingPhase 3
A Phase III Randomized Controlled Trial of Serplulimab Plus Fruquintinib as Adjuvant Therapy for High-Risk Non-Clear Cell Renal Cell Carcinoma
Non-Clear Cell Renal Cell Carcinoma (nccRCC)
RecruitingObservational study
Genetic Analysis of Birt Hogg-Dube Syndrome and Characterization of Predisposition to Kidney Cancer
Kidney Neoplasms, Kidney Cancer
Enrolling by invitation
Use of Tracking Devices to Locate Abnormalities During Invasive Procedures
Adenocarcinoma, Prostate Neoplasms
RecruitingPhase 2/3
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jindřich Šonský, MD principal investigator
Vascular surgery, University hospital Královské Vinohrady, Prague
Alexandra Gregušová, MD study chair
Vascular surgery, University hospital Královské Vinohrady, Prague
Jakub Hanych, MD study chair
Vascular surgery, University hospital Královské Vinohrady, Prague
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Renal Cell Carcinoma (Kidney Cancer) and Benign Renal Neoplasm, run by Charles University, Czech Republic at 1 site in Czechia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 19 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Czechia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Detection-specific renal cell carcinoma (RCC) proportions (time frame: From 2011 to 2020). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Mar 2026.